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Background: Many new approaches have been adopted for the treatment of bipolar disorder (BD) in the past few years,
which strived to produce more positive outcomes. To enhance the quality of care, several guideline recommendations have
been developed. For study purposes, we monitored the prescription of psychotropic drugs administered to bipolar patients
who had been referred to tertiary care services, and assessed the degree to which treatment met specific guidelines.
Methods: Between December 2006 and February 2009, we assessed 113 individuals suffering from BD who had been
referred to the Royal Ottawa Mental Health Centre (ROMHC) Mood Disorders Program by physicians within the community,
mostly general practitioners. The Structured Clinical Interview for DSM-IV-TR was used to assess diagnosis. The prescribed
treatment was compared with specific Canadian guidelines (CANMAT, 2009). Univariate analyses and logistic regression were
used to assess the contribution of demographic and clinical factors for concordance of treatment with guidelines.
Results: Thirty-two subjects had BD type I (BD-I), and 81 subjects had BD type II (BD-II). All subjects with BD-I, and 90% of the
BD-II group were given at least one psychotropic treatment. Lithium was more often prescribed for subjects with BD-I (62%)
than those with BD-II (19%). Antidepressants were the most frequently prescribed class of psychotropics. Sixty-eight percent
of subjects received treatment concordant with guidelines by medication and dose. The presence of a current hypomanic
episode was independently associated with poorer concordance to guidelines. In more than half the cases, the
inappropriate use of antidepressants was at the origin of the non concordance of treatment with respect to guidelines.
Absence of psychotropic treatment in bipolar II patients and inadequate dosage of mood stabilizers were the two other
main causes of non concordance with guidelines.
Conclusions: The factors related to treatment not concordant with guidelines should be further explored to determine
appropriate strategies in implementing the use of guidelines in clinical practice.
Keywords: Bipolar disorder, Pharmacotherapy, Treatment, GuidelinesBackground
Bipolar disorder (BD) is a chronic disease with high risk of
relapse. This disease also results in a high rate of suicidal
mortality [1]. Many treatments have been made available
in recent years to manage BD and to enhance positive out-
come. To improve the quality of care, several guidelines
have been developed with the help of evidence-based
medicine and expert consensus meetings [2-9]. Given the* Correspondence: Sabrina.Paterniti@theroyal.ca
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distribution, and reproduction in any mediumrapid growth in the number of available medications,
some of these guidelines have been updated [10-14]. The
first guidelines which were published in 1997 by the The
Canadian Network for Mood and Anxiety Treatments
(CANMAT) [15] were updated in 2005 [16]. This update
resulted in major modifications in its recommendations
while projecting integrated elements of efficacy, effective-
ness, and side effects. Further updates appeared in 2007
and 2009 [17,18]. CANMAT guidelines pointed out specific
recommendations for bipolar II disorder (BD-II), which
was neglected by most of the previous guidelines.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ject underline the importance of enhanced adherence to
clinical guidelines which can effectively improve the out-
come of bipolar patients. Suppes et al. [19] assessed 141 bi-
polar patients treated in clinics where treatment guidelines
were actively implemented in meetings with clinicians and
in psychoeducational interventions with patients and fam-
ilies. They compared their outcome with that of 126 pa-
tients treated in a standard “as usual” protocol. The first
group of patients showed greater sustained improvement
at the initial and later stages with respect to overall severity
of psychiatric symptoms, as well as in manic symptoms.
For the same group of 141 bipolar patients, stricter adher-
ence to treatment guideline recommendations was associ-
ated with greater reductions in depressive symptoms and
overall psychiatric symptoms over time [20].
Despite the recent emphasis on evidence-based practice,
guideline recommendations are not always implemented.
Perlis [21] found that 34% of psychiatrists reported not
having recourse to guidelines on a regular basis to treat
BD, where only a very small percentage identified guidelines
as their primary source of information. Similar results were
obtained in two other studies conducted in France and
Serbia, where 40% and 34% of psychiatrists, respectively,
had claimed non-use of guidelines in the management of
BD in daily practice [22,23].
The treatment of bipolar patients in concordance with
guidelines varies widely throughout the studies, as shown
in Table 1. Except for the low percentages found in three
studies [24-26], concordance percentages ranged from
50% to 80%. Smith et al. [27] found that concordance ofTable 1 Studies of guideline concordance in bipolar disorder
Population N
Unutzer et al. 2000 [30] Out-patients 1246 BD
Lim et al. 2001 [24] In-patients 1421 BDI
Simon et al. 2004 [31] Out-patients 665 BDI + 239 BDII
Kilbourne et al. 2005 [32] In- and out-patients 2316 BDI
Farrelly et al. 2006 [33] Out-patients 224 mood episodes in
84 BD I and II
Dennehy et al. 2007 [29] Out-patients 469 BDI 198 BDII
Bush et al. 2007 [34] In- and out-patients 2644 BDI
Arvilommi et al. 2007 [25] In- and out-patients BDI – 90 BDII- 101
Smith et al. 2008 [27] In-patients 23 BD
Bauer et al. 2009 [28] 306 (87% BDI)
Altinbas et al. 2011 [26] Out-patients 263 depressive episodes
in 142 patients (131 BDI)
BD Bipolar Disorder, BDI Bipolar Disorder type I, BDII Bipolar Disorder type II, MS Motreatment was 52% in a naturalistic setting, with a percent-
age increasing to 75% after a one-year psychoeducational
intervention aimed at implementing the guidelines. Bauer
et al. [28] found a concordance of 50-60% at the index
hospitalization with respect to 306 participants monitored
through a collaborative care model; there was, however, a
marked decrease after 2 years. Dennehy et al. [29] found
high percentages of concordance with treatment guidelines
among psychiatrists who had participated in extensive
training based on published clinical practice guidelines.
Some factors were linked to better concordance with
guidelines. Manic patients were more likely to receive con-
cordant treatment than patients suffering from depressive
or mixed episodes [33]. The presence of psychotic features
was related to higher percentages of concordance with
treatment guidelines [24,26]. Treatment setting influenced
concordance to treatment guidelines, with in-patients
more frequently receiving adequate treatment than
out-patients [25,34]. Patients diagnosed with anxiety or
depressive disorder before being diagnosed with BD were
less likely to receive antimanic medications and more
likely to receive antidepressants without any antimanic
treatment [34]. In the STEP-BD study, earlier age at onset
and administration of adequate pharmacotherapy at entry
predicted those more likely to receive guideline-concordant
care during new-onset mood episodes [29]. In the same
STEP-BD study [31], bipolar I patients were more likely
to receive adequate treatment as opposed to bipolar II
patients. Arvilommi et al. [25] found that with the lack of
clinical diagnosis of BD at entry, rapid cycling, polyphasic
index episode, as well as depressive index phase, wereGuidelines % Concordance
Expert consensus panel 83%
Expert consensus panel Manic with psychotic features:
38% without: 16%; Depressive with
psychotic features: 31%; without: 17%
Several guidelines BDI: 65.4% BDII: 52.7%
APA and Department of
Veterans Affairs
Bipolar specific MS: 74.6% Any MS or
neuroleptics second generation: 84.4%
British Association for
Psychopharmacology
Manic: 81% Depressive: 64% Mixed: 62%
Several guidelines Depressive: 83.4% Hypomanic/manic:
81.9% Mixed: 81.8%
Several guidelines 67%
Several guidelines BDI: 55.6% BDII: 30.7%
Expert consensus panel 52% in naturalistic settings, increased
to 75% after intervention
Department of Veterans
Affairs
50%-60% at index hospitalization in
collaborative model; declined to
30%-40% after two years
Turkish Psychiatric Association
Guidelines for Bipolar Disorder
Severity of the episode: Mild: 29.%;
Moderate or severe without psychosis:
27.4%; severe with psychos: 87.5%
od Stabilizer, APA American Psychiatric Association.
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study assessing the treatment of veterans suffering from
BD [32], race was not an associative factor in the adminis-
tration of mood stabilizers.
To our knowledge, there has never been a study
conducted on concordant treatment of bipolar patients
in keeping with the CANMAT guidelines in Canada. The
first object of our study was to examine the administration
of psychotropic drugs among subjects diagnosed with BD
and who had been referred to tertiary care services. The
second objective was to assess concordance of prescribed
treatments with Canadian guidelines. The third objective
was to identify the clinical factors linked to poorer
concordance of treatment with CANMATguidelines.
Methods
Sample
The study “Prevalence, comorbidity and psychosocial risk
factors: recurrent unipolar depression and bipolar disorder”
was realized in the context of the Assessment and Treat-
ment Clinic (ATC), an out-patient service established in
2006 within the framework of the Royal Ottawa Mental
Health Centre (ROMHC) Mood Disorders Program. The
ROMHC Mood Disorders Program provides specialized
tertiary care service to all citizens of Ottawa, Ontario
(estimated population in 2009: 885,715 inhabitants). It
targets the population of high-risk mood disorder patients,
namely, individuals with serious, complex, and/or rare
mental disorders, who present multiple and complex
needs, and whose treatment requirements cannot be met
in the first line or at the more intensive levels of service. As
such, these patients require more intensive and prolonged
care resources. The study protocol was approved by the
Research Ethics Board of ROMHC (Reference: REB#2006-
22). A written informed consent was obtained from partici-
pants, where the rational of the study was explained and
the participants gave consent to publish the results of the
study, but kept their identity confidential.
The selection of the cases to be assessed by the ATC
was as follows. A nurse examined all the referrals from
community doctors (mostly family physicians) to the
mood disorders program and chose the referrals which
were the most likely to satisfy the criteria for the program,
that is, subjects suffering from primary recurrent or
chronic unipolar major depressive disorder or BD, were
resistance to treatment, or severity required the interven-
tion of the outpatient multidisciplinary team. About 20%
of all referrals were included and assessed by the ATC
team through a diagnostic and clinical assessment, so a
standardized diagnosis was available only for these patients.
The psychiatrists of the program assessed the remaining
cases, making recommendations for treatment or following
the patients as appropriate. From December 2006 to
February 2009, the ATC assessed 409 subjects, whowere referred to the program by physicians within the
community; mostly family physicians. Of these subjects,
113 (39 men and 74 women) presented with primary
diagnosis of BD type I or II.
Diagnostic and clinical assessment
During the course of the initial visit, subjects underwent
clinical interviews with a nurse, a social worker, an occupa-
tional therapist, a psychiatrist and a psychologist. Collection
of information took on average 3 to 5 hours.
The Structured Clinical Interview for DSM-IV-TR (SCID)
[35] was used to assess diagnosis on Axis I. The SCID
screen was administered to all patients which included
Mood and PTSD modules completed for every patient.
Where anxiety, psychotic, or eating disorder was indicated
based on SCID screening, these modules were administered
as well. Substance abuse and dependence were flagged
based on the chart review and the patient’s report during
the interdisciplinary assessment. The correspondent module
was administered where indicated.
In cases where a diagnosis of BD proved inconclusive
with the use of SCID-I (“rule out diagnoses”), all efforts
were made to produce a valid diagnosis, by consulting
the charts and/or interviewing the treating psychiatrist.
The psychotropic medications that were prescribed and
their dosages were recorded by a nurse. The lithium
levels were measured in the following month after the
first assessment. A history of previous hospitalizations
was also systematically collected by a nurse.
Criteria: adherence to treatment guidelines
The CANMAT guidelines published in 2009 [18] were
considered for purposes of evaluating treatment concord-
ant with guidelines. CANMAT guidelines include first,
second, and third line recommendations, where second
and third line recommendations should be used when the
first line are not effective, or not tolerated, or not indicated
for other reasons. A systematic longitudinal pharmaco-
logical history of every patient was not available, so we
could not verify if patients treated with second or third line
treatments had already been prescribed with a treatment
following a first line recommendation. However, our sample
included patients referred to a tertiary care structure and
the selection process of the sample included the criteria
of having a resistant-to-treatment, or chronic, severe and
highly recurrent disorder. In these cases, it is likely that
the patients had already been prescribed with at least a
first line treatment. For this reason, we considered second
and third line treatments as concordant to guidelines.
Using the Structured Clinical Interview for DSM-IV
(SCID) [35], we identified the nature of a given mood
episode present in any month preceding the assessment
(“current episode”). For cases exhibiting a current depressive
episode, treatment was compared with recommendations
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cated in the Table four point three of the above publication
[18] and BD-II (Table seven point two) [18]. For cases of
hypomania, treatment was compared with recommenda-
tions for “acute mania” (Table three point three) [18]; other-
wise, treatment was compared with recommendations for
“maintenance treatment” for BD-I (Table five point five) and
BD-II (7.4) [18]. No cases of acute mania were described
among bipolar I patients at the moment of assessment.
Prescriptions for lithium, anticonvulsants, atypical anti-
psychotics, and antidepressants were considered for pur-
poses of assessing prescribed treatments as concordant
with the CANMAT guidelines, whether they were associ-
ated or not with benzodiazepines, zopiclone, or first gener-
ation neuroleptics. Although CANMAT guidelines do not
explicitly specify the dose ranges for the recommended
treatments, the recommendations are mainly based on
clinical trials. Based on the results of these trials, we con-
sidered the following dosages to define a treatment as be-
ing in the “therapeutic range”, so following the CANMAT
recommendations: lithium blood levels ≥0.5 mEq/L; val-
proate ≥ 750 mg daily; carbamazepine ≥600 mg daily;
lamotrigine ≥ 50 mg daily; olanzapine ≥ 5 mg daily; risper-
idone ≥ 2 mg daily; quetiapine ≥150 mg daily.
The following exceptions were made: 1) trazodone at low
dosage (≤50 mg) was not considered as “antidepressant”,
given its use as a hypnotic; 2) amitryptyline at low dosage
(<50 mg) was not considered an antidepressant, given
its use as an anti-pain or hypnotic under low dosage.
“Polypharmacy” was defined as the association of more
than one mood stabilizer, atypical antipsychotic and anti-
depressant, where at least one of the prescribed treatments
met the CANMAT recommendations, though in combi-
nations not specifically recommended by the guidelines.
The classification “doesn’t follow the guidelines” refers
to patients not receiving any treatment included in the
CANMAT recommendations.
Data analysis
Data was analyzed using SPSS 19.0 statistical package
(PASW, Chicago, IL). Pearson χ2 test and t-tests were used
where appropriate. Bonferroni corrections were used in the
analyses. We considered the following analyses: 1) in de-
scriptive statistics, we compared the proportions of subjects
taking at least one of the different classes of psychotropics
at any dosage (lithium, anticonvulsants, antidepressants,
benzodiazepines, neuroleptics, at least one psychotropic
drug) by type of bipolar disorder (BD-I or BD-II) and
nature of the mood episode (hypomanic, depressive,
euthymia). Two-tailed tests were considered as significant
when p < 0.001. 2) We then compared the proportions of
subjects taking at least one mood stabilizer or atypical anti-
psychotic with a dosage in the therapeutic range, by type of
BD and nature of the mood episode. Two-tailed tests wereconsidered as significant when p < 0.001. 3) Finally, we com-
pared the proportions of patients prescribed with guideline-
concordant treatment for the following predictors: sex; age;
previous hospitalizations; type of BD; nature of the current
mood episode; comorbid anxiety disorder (current); comor-
bid substance use disorder (current); age at onset of the
mood disorder. Two-tailed tests were considered as signifi-
cant when p < 0.006. A logistic regression model was used
to predict the independent likelihood of receiving treatment
not concordant with guidelines.
Results
Characteristics of the sample
Sampling consisted of 32 patients diagnosed with BD- I,
and 81 with BD-II. Sex and age were similar for both
samples: two-thirds being female (N = 74, 65.5%); average
age (SD) being 38.7 (11.2).
Prevalence of psychotropic prescriptions by type of BD
All bipolar I patients and 90% of bipolar II patients were
administered at least one psychotropic drug. Table 2 shows
the number of patients receiving specific psychotropics, at
any dosage. Statistical comparisons between BD-I and II
were performed for classes of psychotropics only. Lithium
was prescribed for one-third of the sample, more fre-
quently in BD-I than BD-II. Among patients prescribed
with lithium, a similar percentage of bipolar I and II pa-
tients were prescribed an adequate dosage, with serum
levels ≥0.5 mEq/L (BD-I: N = 16 (80%); BD-II: N = 12
(80%). The median value of lithium serum levels were 0.59
and 0.79 in BD-I and II, respectively.
Anticonvulsants were prescribed for approximately 40% of
the sample; more than 60% of bipolar patients were pre-
scribed antidepressants. Second generation neuroleptics
were prescribed much more frequently than first generation.
Prescriptions for anticonvulsants, antidepressants, benzodi-
azepines and neuroleptics were not significantly different in
the two types of BD. Bipolar I patients were more likely be
prescribed with at least one mood stabilizer or atypical anti-
psychotic at therapeutic range than bipolar II patients (BD-I:
84% vs BD-II: 49%, χ2 = 11.6, df = 1, p < 0.001).
Our sample included only a minority of patients treated
with one single mood stabilizer within monotherapy (lith-
ium, lamotrigine, valproate, or carbamazepine), without be-
ing prescribed any antidepressants or second generation
antipsychotics (bipolar I patients: N = 11 (34%); bipolar II
patients: N = 12 (15%).
Psychotropic medications administered by nature of
mood episodes
No significant differences were found in the prescrip-
tions by the nature of the mood episode, although there
was a trend for subjects with a current depressive epi-
sode to be prescribed antidepressants more frequently
Table 2 Psychotropic treatment by type of bipolar disorder among patients attending an out–patient tertiary care service
Bipolar I disorder (N = 32) Bipolar II disorder (N = 81) Total Daily dosage min–max
N (%) N (%) N (%) Mg
Lithium 20 (62.5) 15 (18.5) * 35 (31.0) 300–1950
Anticonvulsants 10 (31.3) 36 (44.4) † 46 (40.7)
Valproate 3 (9.4) 14 (17.3) 17 (15) 250–2000
Carbamazepine 1 (3.1) 0 1 (0.9) 600
Lamotrigine 6 (18.8) 13 (16) 19 (16.8) 50–500
Gabapentin 1 (3.1) 6 (7.4) 7 (6.2) 300–1600
Topiramate 1 (3.1) 9 (11.1) 10 (8.8) 25–200
Levetiracetam 0 1 (1.2) 1 (0.9) 250
Antidepressants 17 (53.1) 54 (66.7) † 71 (62.8)
SSRIs 7 (21.9) 27 (33.3) 34 (30.1)
Citalopram 4 (12.5) 10 (12.3) 14 (12.4) 20–80
Escitalopram 1 (3.1) 12 (14.8) 13 (11.5) 5–40
Fluoxetine 1 (3.1) 1 (1.2) 2 (1.8) 20
Fluvoxamine 1 (3.1) 0 1 (0.9) 200
Paroxetine 0 2 (2.5) 2 (1.8) 40–60
Sertraline 0 2 (2.5) 2 (1.8) 100–200
SNRI 9 (28.1) 13 (16.0) 22 (19.5)
Duloxetine 0 1 (1.2) 1 (0.9) 60
Venlafaxine 9 (28.1) 12 (14.8) 21 (18.6) 75–300
Moclobemide 0 1 (1.2) 1 (0.9) 600
Antidepressants Tricyclic 1 (3.1) 5 (6.2) 6 (5.3)
Amitriptyline 1 (3.1) 4 (4.9) 5 (4.4) 10–100
Trimipramine 0 1 (1.2) 1 (0.9) 50
Other antidepressants 6 (18.8) 27 (33.3) 33 (29.2)
Bupropion 2 (6.3) 13 (16.0) 15 (13.3) 100–450
Mirtazapine 0 4 (4.9) 4 (3.5) 7.5–60
Trazodone 5 (15.6) 13 (16.0) 18 (15.9) 50–200
Anxiolytics benzodiazepines 10 (31.3) 16 (19.8) † 26 (23.0)
Neuroleptics 18 (56.3) 33 (40.7) † 51 (45.1)
Neuroleptics first generation 2 (6.3) 4 (4.9) 6 (5.3)
Methotrimeprazine 1 (3.1) 4 (4.9) 5 (4.4) 10–125
Trifluoperazine 1 (3.1) 0 1 (0.9) 3
Neuroleptics second generation 17 (53.1) 30 (37.0) 47 (41.6)
Olanzapine 7 (21.9) 6 (7.4) 13 (11.5) 2.5–20
Quetiapine 8 (25.0) 18 (22.2) 26 (23.0) 12.5–450
Risperidone 2 (6.3) 8 (9.9) 10 (8.8) 0.5–2.00
Stimulants – methylphenidate 0 1 (1.2) 1 (0.9) 5
Hypnotics – Zopiclone 0 5 (6.2) 5 (4.4) 3.75–30
No psychotropics 0 8 (90.0) 8 (7.0)
* p < 0.001 † NS.
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df = 1, p < 0.02) (Table 3). Especially noteworthy was
the relatively frequent prescription of antidepressants to
subjects suffering from current hypomanic episodes
(43% in BD-I and 56% in BD-II).Prescriptions concordant with CANMAT guidelines
Eight-four patients (74.3%) were prescribed with at least
one treatment congruent with CANMAT guidelines when
considering only the type of the treatment. When we con-
sidered type and therapeutic dosage, the number decreased
Table 3 Classes of psychotropic treatment by type of bipolar disorder and nature of current mood episode
Bipolar I disorder (N = 32) Bipolar II disorder (N = 81)
Hypomania Depression Euthymia Hypomania Depression Euthymia
N = 7 N = 18 N = 7 N = 18 N = 47 N = 16
N (%) N (%) N (%) N (%) N (%) N (%)
Lithium 4 (57.1) 11 (61.1) 5 (71.4) 3 (16.7) 8 (17.0) 4 (25.0)
Anticonvulsants 2 (28.6) 5 (27.8) 3 (42.9) 7 (38.9) 25 (53.2) 4 (25.0)
Antidepressants 3 (42.9) 13 (72.2) 1 (14.3) 10 (55.6) 34 (72.3) 10 (62.5)
Neuroleptics 3 (42.9) 11 (61.1) 4 (57.1) 7 (38.9) 20 (42.6) 6 (37.5)
First generation 0 1 (5.6) 1 (14.3) 1 (5.6) 3 (6.4) 0
Second generation 3 (42.9) 11 (61.1) 3 (42.9) 6 (33.3) 18 (38.3) 6 (37.5)
Benzodiazepines 0 7 (38.9) 3 (42.9) 3 (16.7) 8 (17.0) 5 (31.3)
At least one MS or AAP in therapeutic range* 7 (100) 15 (83.3) 5 (71) 8 (44.4) 26 (55.3) 6 (37.5)
At least one psychotropic drug 7 (100) 18 (100) 7 (100) 16 (88.9) 44 (93.6) 13 (81.3)
*MS or AAP in therapeutic range: lithium serum levels ≥0.5 mEq/L; valproate ≥750 mg daily; carbamazepine ≥600 mg daily; lamotrigine ≥50 mg daily; olanzapine
≥5 mg daily; risperidone ≥2 mg daily; quetiapine ≥150 mg daily.
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number of patients prescribed with at least one treatment
concordant with guidelines for both type and dosage was
24 (75%); 4 (12%) bipolar I patients were prescribed with at
least one treatment concordant for type but not for dosage.
The corresponding figures for BD-II were 53 (65.4%) and 3
(4%), respectively. Of the 47 bipolar II patients in a depres-
sive phase, 12 patients were prescribed antidepressants
within monotherapy, which is classified as a third line
recommendation under the CANMAT guidelines.
The reasons for non-concordance with guidelines ap-
peared to vary according to the nature of the episode
(Table 5). A high percentage of subjects with current
hypomanic episodes were prescribed with no treatment
concordant with guidelines (17 out of 25 patients, 68%);
in 13 of these 17 cases, subjects were prescribed antidepres-
sants. Ten bipolar II patients in a hypomanic phase were
prescribed with antidepressants. Six of these patients had
“mixed” depressive-hypomanic symptoms corresponding
to a “dysphoric” state, and two patients presented rapidTable 4 Treatment concordant with CANMAT guidelines by m
disorder and by nature of current episode
Bipolar I disorder (N
Hypomania Depression
N = 7 N = 18
Follows guidelines strictly 4 (57.1%) 8 (44.4%)
First line treatment 4 (57.1%) 5 (27.8%)
Second line treatment 0 1 (5.6%)
Third line treatment 0 2 (11.1%)
Polypharmacy with at least one treatment
recommended in guidelines
0 7 (38.9%)
No treatment following the guidelines 3 (42.9%) 3 (16.7%)
*Treatment concordant for type and dosage of prescribed mood stabilizers.cycling. The remaining two patients had mild to moderate
hypomanic symptoms. Among subjects for whom treat-
ment non-concordant with guidelines was prescribed, a
total of 11 patients were prescribed antidepressants without
any mood stabilizer.
Factors associated with the prescription of at least one
treatment concordant with guidelines by type and
dosage of the medication
The associations between several clinical factors and treat-
ment concordant with guidelines (Table 6) were studied.
Univariate analyses showed that hypomanic patients
presented poorer guideline concordance (p < 0.001).
There was also a similar non significant trend for patients
having had no previous hospitalizations (p < 0.05) and
presenting a current substance disorder (p < 0.06).
To test the independent association of the same variables
with a poorer concordance of treatment to guidelines, we
performed a logistic regression, where concordant treat-
ment with guidelines was the dependent variable (0 =edication and dosage in bipolar patients, by type of
= 32) Bipolar II disorder (N = 81)
Euthymia Hypomania Depression Euthymia Total
N = 7 N = 18 N = 47 N = 16 N = 113
4 (57.1%) 3 (16.7%) 29 (61.7%) 4 (25.0%) 52 (46.0%)
3 (42.9%) 3 (16.7%) 0 1 (6.3%) 16 (14.2%)
1 (14.3%) 0 14 (29.8%) 3 (18.8%) 19 (16.8%)
0 0 15 (31.9%) 0 17 (15.0%)
1 (14.3%) 1 (5.6%) 14 (29.8%) 2 (12.5%) 25 (22.1%)
2 (28.6%) 14 (77.8%) 4 (8.5%) 10 (62.5%) 36 (31.9%)
Table 5 Reasons for non-concordance of treatment with guidelines
Bipolar I disorder with
no treatment concordant
with guidelines (N = 8)
Bipolar II disorder with
no treatment concordant
with guidelines (N = 28)
Hypomania Depression Euthymia Hypomania Depression Euthymia Total
N = 3 N = 3 N = 2 N = 14 N = 4 N = 10 N = 36
No psychotropics 0 0 0 2 3 3 8 (22.2%)
Antidepressants without any mood stabilizer 0 1 0 5 - 5 11 (30.6%)
Antidepressants in hypomania 3 - - 5 - - 8 (22.2%)
Low dosage of treatment 0 2 2 1 1 1 7 (19.4%)
Other prescriptions of psychotropics, not
following guidelines
0 0 0 1 0 1 2 (5.6%)
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vious hospitalizations, age at onset, current anxiety disorder,
current substance use disorder, type of BD (type I = 0, type
II = 1) and nature of the current episode (depressive or
euthymia = 0; hypomanic = 1) were entered as independentTable 6 Number (%) of subjects receiving at least one treatm
medication, by clinical and sociodemographic factors








Type of bipolar disorder
Type I 24 (75.0%)
Type II 53 (65.4%)




Comorbid anxiety disorder (current)
Present 19 (67.9%)
Absent 58 (68.2%)




Age (mean ± SD)
Treatment – concordant 39.8 ± 11.3
Treatment – not concordant 36.3 ± 10.7
Age at onset (mean ± SD)
Treatment – concordant 22.4 ± 8.0
Treatment – not concordant 25.5 ± 9.0variables. Analysis was adjusted for sex and age. The nature
of the episode was treated as a dichotomic variable, because
of the small numbers. Actual age and age at onset
were entered as continuous variables. Only the nature of
the mood episode was independently associated withent following CANMAT guidelines by type and dosage of
ncordant
(%)
N Degree of freedom Χ2 P
39 1 0.06 0.81
74
53 1 3.91 0.05
60
32 1 0.97 0.32
81
25
65 2 32.7 0.001
23
28 1 0.001 0.97
85
28 1 3.64 0.06
85
N t-test P
77 1 1.58 0.18
36
77 1 1.72 0.09
36
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predicting poorer concordance (hypomania vs. depressive
and euthymic: OR (95% CI) = 7.34 (2.6 to 20.8), p < 0.001).
Discussion
Prevalence of psychotropic treatment
Only 7% of the patients were treatment-free; antidepres-
sants were the most prescribed treatment, especially in
BD-II; lithium was administered to 62% of the bipolar I
patients and only 18% of the bipolar II patients.
In comparing the findings of our study with the results
from scientific literature, we noticed that the percentage
of patients not given any psychotropics in our sample was
similar to results taken from previous studies conducted
within academic centres or teaching hospitals where per-
centages ranged from 2% to 8% [36-39] were noted.
Verdoux et al. [40] found lower percentages (0.9%) in hos-
pital settings. Higher percentages (ranging between 16%
and 22%) were found by Blanco et al. [41], examining data
on a nationally representative group of visits to psychia-
trists in an office-based practice within the US.
In our study, the global percentage of patients given
lithium was 31%, which is in the low range of percent-
ages found in other studies, ranging from 30% to 53%
[36-38,40-46]. This low rate is comparable with that
observed in the United States where the percentage of
bipolar patients prescribed with lithium has decreased
from 50.9% in 1992–95 to 30.1% in 1996–99, based on
the National Ambulatory Medical care survey [41]. By
contrast, European countries show a higher percentage
of lithium use compared with the United States
[36-38,40,42-46]. Decrease in lithium use has paralleled
the increased use of valproate (from 10.9% to 26.6%) [41],
and of second generation antipsychotics, (from 1.2% to
17.0% in Blanco et al. [41]; see also Hayes et al. [47]
Pillarella et al. [48]). The low percentage of lithium use
found in our study may well reflect the general North-
American trend. Our study actually indicates both second
generation antipsychotic and valproate use rates as being
relatively high (41.6% and 15.0%, respectively), and this
was consistent with the increasing trends in the use of
such medications over the past decade.
In conducting our study, the type of BD appeared to
be an important factor in predicting the use of lithium,
with BD-I recording a much higher proportion of lith-
ium users. This result is at odds with the STEP-BD data
[46] which indicates a similar percentage of lithium
users in BD-I and II (39.4% and 35.7%, respectively). On
the other hand, Arvilommi et al. (2007) found that bipo-
lar I patients were prescribed with mood stabilizers more
often than bipolar II patients, which is consistent with
our results, where the percentage of bipolar I patients
taking at least one mood stabilizer or atypical anti-
psychotic in the therapeutic dosage was almost doublethan in bipolar II patients. This might not only reflect
the CANMAT guidelines, but also the perceived lower
degree of severity in BD-II and low consistency diagno-
sis. In our sample, about 20% of patients taking lithium
had levels below the therapeutic range, which is consist-
ent with the results of previous studies [30,36].
The percentage of bipolar patients given antidepres-
sants in our study (62.8%) was similar to that found in
similar studies conducted in North America. In the
United States studies, corresponding percentages range
from 40% to 74% [41,44-46,49,50]. Studies by Blanco
et al. [41] indicate a constant pattern in the use of anti-
depressants between 1992–1995 and 1996–1999 (45.8%
and 45.7%, respectively). As expected, bipolar patients
with depressive episodes seemed to be more likely to
take antidepressants than other bipolar patients in our
study. A similar trend was observed in the STEP-BD
study [46].
Interestingly, there is also a transatlantic difference in
antidepressant use, more frequent in the United States
than in Europe [42] In UK studies, the percentage of
antidepressant use varies from 14.3% to 38% [36-38,43],
whereas in France, Verdoux [40] et al. found 34.2% of
bipolar patients prescribed with antidepressants.
In our sample, no bipolar patients were prescribed
aripiprazole or ziprasidone, although CANMATguidelines
specifically recommended the two atypical antipsychotics
in the treatment of BD-I since 2005 [16]. This can be due
to the fact that Health Canada approved their use in the
treatment of bipolar disorder only in 2009.
In our sampling, monotherapy with mood stabilizers
was not a frequent approach, consistent with literature
on the subject where only a minority of bipolar patients
benefited from monotherapy treatment with lithium or
other mood stabilizer (Ahmed and Anderson [36]: 23%;
Frangou et al. [43]: 23.8%; Lloyd et al. [38]: 29%; Ghaemi
et al. [46]: 10.8%; Verdoux et al. [40]: 14%).
In recent years, polytherapy has been used more
frequently in clinical practice [44,51]. Polytherapy is more
commonly administered for depressed bipolar patients
where monotherapy is much less efficacious [52], while
guidelines for acute mania recommend monotherapy with
mood stabilizers or antipsychotics. The high frequency of
polytherapy noted in our study may well reflect the higher
prevalence of depression; it also suggests that the severe
state of patients referred to our tertiary care services are
more likely to have comorbidities or disorders resistant to
treatment.
Concordance with treatment guidelines
Treatment was congruent with guidelines in 68% of our
sampling cases, when both type and dosage of the medica-
tions were considered. This percentage was quite high
when compared with other studies. The larger spectrum
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compared with other guidelines, can partially explain this
result [53].
Divergence from guidelines was mostly noted for pa-
tients suffering from hypomania, with 68% of hypomanic
patients receiving non-concordant treatment to guidelines.
In more than half of the cases, treatments not congruent
with guidelines were due to inappropriate treatments with
antidepressants; the remaining cases of non-concordance
were due to the absence of psychotropic treatment or to
inadequate dosage. Also noteworthy is that more than
one-third of depressed bipolar II patients receiving
treatment concordant with guidelines were prescribed
antidepressants within monotherapy, which constitutes a
third line recommendation under the CANMATguidelines,
and almost one third of all bipolar II patients were treated
with antidepressant without any mood stabilizer.
The use of antidepressants for bipolar depression is still
controversial. The major criticism regarding use of antide-
pressants in instances of bipolar depression is based on the
risk of destabilizing mood, switching into mania or hypo-
mania [54-56] or increasing the cycle frequency [57,58].
Such negative effects appear to be limited to certain classes
of antidepressants [59-61]. Factors which appear to increase
the risk of destabilization are: presence of mixed states
[62,63], subthreshold manic symptoms at baseline [64] and
BD-I (versus BD-II) [65,66], which suggests that different
subpopulations may present different vulnerabilities to
affective switching. In the STEP-BD study, approximately
15% of bipolar patients receiving long-term treatment with
antidepressants developed a chronic irritable dysphoric
state (ACID syndrome). The study indicated that the risk
of developing ACID symptoms was linked to a previous
history of antidepressant-induced affective switch, and to
female gender [67]. Finally, the use of antidepressants may
significantly increase the risk of suicidal ideation [68].
The efficacy of antidepressants in the acute treatment
of bipolar depression is uncertain. The STEP-BD study
showed similar efficacy comparing lithium or divalproex,
alone or associated with an antidepressant [61]. In his
meta-analysis, Gijsman et al. [69] suggested antidepressants
as being effective in the short-term treatment of bipolar de-
pression, but in a more recent meta-analysis, antidepres-
sants were found not to be superior in any way to placebos
in the acute treatment of bipolar depression [70]. Then
again, Altshuler et al. [71] suggested the usefulness of
maintaining antidepressant treatments within the subpopu-
lation of patients who require both a mood stabilizer and
an antidepressant to achieve complete remission from de-
pressive episodes. Also controversial is the efficacy of long-
term treatment with antidepressants in protecting patients
from the recurrences of bipolar depression [55,72]. A meta-
analysis of seven trials involving long-term treatments con-
cluded that long-term adjunctive antidepressant treatmentswere not superior to mood stabilizers alone in protecting
patients from recurrences, and that antidepressant mono-
therapies were associated with higher risks of mania or
hypomania relapses [73].
Antidepressants administered within monotherapy are
contraindicated for BD-I, because of the high risk of indu-
cing mania or rapid cycling [54]. However, the risk/benefits
may be different in BD-I and BD-II, and some studies sug-
gest the efficacy and safety of antidepressant monotherapies
in the treatment of BD-II [74-77]. CANMAT guidelines
recommend antidepressants associated with mood stabi-
lizers or atypical antipsychotics in the treatment of acute
bipolar depression. Antidepressant monotherapy is only
recommended as a third line treatment for BD-II, particu-
larly for those with infrequent hypomanias [18].
Finally, though there is agreement on the different
guidelines in the discontinuance of treatment with antide-
pressants during manic episodes, nevertheless they are at
times prescribed in cases of acute mania in clinical practice
[33,78]. Within our sampling, antidepressants were pre-
scribed to certain bipolar II patients suffering from current
hypomanic symptoms with “mixed” depressive symptoms
or with rapid cycling. In both of these conditions, anti-
depressant treatment is specifically contraindicated [63].
Non-concordant treatment with guidelines observed
in our sample can be explained in different ways. First,
the diagnosis of BD, especially type II, can be difficult at
the onset of the disorder. In most cases, BD-II patients
consult their doctor during the depressive phase, not
during the hypomanic phase. Identifying the hypomanic
episodes in BD-II can be difficult if appropriate questions
are not asked, or if family members are not properly
interviewed. Thus, before it is finally recognized, BD can
be diagnosed as a recurrent depression over several
years [79-82]. Some of the patients in our sample were
misdiagnosed as having recurrent major depressive dis-
order. The second possible reason is that treatment with
antidepressants, administered during episodes of depres-
sion or for purposes of preventing further episodes, is not
suspended during a hypomanic phase, either because
patients do not require medical intervention or because
symptoms are not recognized. There is no consensus in
the current guidelines on criteria governing time frames
necessary to interrupt antidepressants [53], which can
create confusion as to the appropriate discontinuation of
antidepressants following depressive episodes. It is note-
worthy that the CANMAT guidelines do not make explicit
recommendations for BD-II hypomania, leaving some po-
tential confusion for the reader whether recommendations
for acute mania have to be adopted. Patients not adhering
to treatment with mood stabilizers [83-85] is a third pos-
sible factor which explains the frequency of treatment
with antidepressants, especially in monotherapy. Finally,
there remains the possibility of general practitioners
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agreement, or lack of familiarity.
Although the study focused on patients seen between
the end of 2006 and beginning of 2009, we decided to
use the 2009 guidelines rather than 2007, as some of the
recommendations adopted in 2009 were already suggested
in the previous version. For example, the possibility to use
antidepressant monotherapy in bipolar II patients in
depressive phase was already described in 2007, and more
explicitly formulated in 2009. Other new recommendations
adopted in the 2009 CANMAT version, which could
potentially affect the percentage of concordance with
guidelines in our sample, concerned with the use of
quetiapine monotherapy as first line recommendation
of BD-II depression and in BD-I maintenance; the use of
divalproex monotherapy as second line recommendation
in BD-I and BD-II depression; and the use of quetiapine
in combination with lithium or divalproex in BD-I
maintenance. In our sample, only two treatments
would have been classified in a different way if we had
adopted the 2007 guidelines: two BD-II depressive patients
taking divalproex monotherapy would have been clas-
sified as “doesn’t follow guidelines”, instead of “second
line treatment”.
Our study, however, dealt with limitations. Our sample
was relatively small, most notably as far as stratification
was concerned. Also, we had to contend with a strong
representation of depressed patients, which corresponds
to a higher prevalence of depressive symptoms in the
bipolar population.
Conclusions
In conclusion, the actual results support the efficacy of
efforts made over the past years in attempting to com-
municate CANMAT guidelines. Our studies indicate a
relatively high rate of concordance to guideline treatment
by general practitioners. A significant caveat was identified,
however, in the use of antidepressant medications, espe-
cially with respect to treatment of bipolar patients with
hypomanic symptoms. Our study identifies the inappropri-
ate use of antidepressants as one of the factors in outlining
non-concordant treatment with guidelines. Although there
is no evidence supporting the widespread use of antide-
pressants in BD, and moreover, that there be evidence
supporting the use of other agents in its treatment, antide-
pressants remain the most frequently prescribed class of
psychotropic medications in this regard. In the absence of
across-the-board consensus on the use of antidepressants
in treating BD, physicians have to individualize the risk/
benefits for each patient, and repeatedly reassess and re-
evaluate the need for antidepressants, which makes the
treatment of bipolar patients particularly challenging.
Given the high prevalence of depressive symptoms in bipo-
lar patients, it appears that the symptoms, rather than thedisorder, are often the target for treatment. Future research
and intervention can change the current practice [86]. A
recent study [87] has shown that educational programs
were the best means of increasing the likelihood of general
practitioners correctly assigning a subtype diagnosis in the
treatment of BD, and prescribing mood stabilizers instead
of antidepressants.
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